Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus
Abstrakt
Background and aims This multicenter trial compared immediate-release tacrolimus (IR-T) vs prolonged-release tacrolimus (PR-T) in de novo kidney, liver, and heart transplant recipients aged <16 years. Each formulation had similar pharmacokinetic (PK) profiles.
Follow-up efficacy and safety results are reported herein. Materials and methods Patients, randomized 1:1, received once-daily, PR-T or twice-daily, IR-T within 4 days of surgery.
After a 4-week PK assessment, patients continued randomized treatment for 48 additional weeks. At Year 1, efficacy assessments included the number of clinical acute rejections, biopsy-confirmed acute rejection (BCAR) episodes (including severity), patient and graft survival, and efficacy failure (composite of death, graft loss, BCAR, or unknown outcome).
Adverse events were assessed throughout. Results The study included 44 children.
At Year 1, mean +/- standard deviation tacrolimus trough levels were 6.6 +/- 2.2 and 5.4 +/- 1.6 ng/mL, and there were 2 and 7 acute rejection episodes in the PR-T and IR-T groups, respectively. No cases of graft loss or death were reported during the study.
The overall efficacy failure rate was 18.2% (PR-T n = 1; IR-T n = 7). Conclusions In pediatric de novo solid organ recipients, the low incidence of BCAR and low efficacy failure rate suggest that PR-T-based immunosuppression is effective and well tolerated to 1-year post-transplantation.